1. Home
  2. OFG vs RAPP Comparison

OFG vs RAPP Comparison

Compare OFG & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OFG Bancorp

OFG

OFG Bancorp

HOLD

Current Price

$46.77

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$35.33

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFG
RAPP
Founded
1964
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2012
2024

Fundamental Metrics

Financial Performance
Metric
OFG
RAPP
Price
$46.77
$35.33
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$45.17
$48.50
AVG Volume (30 Days)
214.8K
241.6K
Earning Date
04-21-2026
05-08-2026
Dividend Yield
3.12%
N/A
EPS Growth
8.27
24.34
EPS
1.26
N/A
Revenue
N/A
N/A
Revenue This Year
$11.56
N/A
Revenue Next Year
$1.29
N/A
P/E Ratio
$36.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.71
$10.57
52 Week High
$46.85
$42.27

Technical Indicators

Market Signals
Indicator
OFG
RAPP
Relative Strength Index (RSI) 61.47 45.86
Support Level $44.15 $33.55
Resistance Level N/A $41.18
Average True Range (ATR) 0.87 1.91
MACD 0.08 -0.36
Stochastic Oscillator 75.88 22.71

Price Performance

Historical Comparison
OFG
RAPP

About OFG OFG Bancorp

OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: